Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01 Clinical Trial Optional)
The goal of this Funding Opportunity Announcement (FOA) is to support innovative research to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. This FOA supports both mechanistic research and clinical trials. Proposed projects must be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK).
Funding Opportunity Details
February 13, 2018
March 13, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.